Core Viewpoint - Vanda Pharmaceuticals' shares are experiencing an increase following the FDA's approval of Bysanti, a new treatment for bipolar I disorder and schizophrenia, marking a significant milestone for the company [1][2]. FDA Approval - The FDA has approved Bysanti as a first-line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for schizophrenia in adults [2]. - Bysanti is classified as a new chemical entity (NCE) and belongs to the atypical antipsychotics category [2]. Clinical Studies - In clinical studies, Bysanti showed bioequivalence to iloperidone across the therapeutic dosing spectrum, leveraging established efficacy and safety knowledge from the clinical development program and over 100,000 patient-years of real-world experience with Fanapt (iloperidone) [3]. - Fanapt's net product sales reached $33.2 million in Q4 2025, reflecting a year-over-year increase of 25% [3]. Commercial Roadmap - Bysanti is expected to be commercially available in Q3 2026, with marketing exclusivity protected by regulatory data exclusivity and US patents expiring in 2044 [4]. - Bysanti is also being tested as a once-daily adjunctive treatment for treatment-resistant major depressive disorder, with ongoing clinical studies expected to conclude by the end of this year [4]. Technical Analysis - The stock is currently trading 5.5% below its 20-day simple moving average (SMA) and 10.2% below its 100-day SMA, indicating short-term weakness [5]. - Over the past 12 months, shares have increased by 25%, and they are closer to their 52-week highs than lows, suggesting strong long-term performance [5]. - The RSI is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [5][6]. Analyst Consensus & Recent Actions - The stock carries a Buy Rating with an average price target of $18.10 [7]. - Recent analyst actions include: - HC Wainwright & Co. raised the target to $22.00 with a Buy rating [7]. - B. Riley Securities raised the target to $14.00 with a Buy rating [7]. - Jefferies raised the target to $7.50 with a Hold rating [7]. - Vanda Pharmaceuticals shares were up 35.59% at $7.81 during premarket trading [7].

Core Insights - Vanda Pharmaceuticals, Inc. (VNDA) received FDA approval for its drug tradipitant, branded as Nereus, for preventing motion sickness-induced vomiting, marking the first new pharmacologic therapy for this condition in over 40 years [1][2][8] - Following the announcement, VNDA shares surged 18% in after-hours trading on December 30 and continued to rise in pre-market trading on December 31 [1][8] Company Developments - The efficacy of Nereus is backed by three clinical studies, including two phase III trials conducted at sea, demonstrating its effectiveness in individuals with a history of motion sickness [3] - VNDA is also exploring tradipitant for other conditions, including gastroparesis and nausea associated with GLP-1 receptor agonists, which are common side effects in obesity and diabetes treatments [4] - VNDA's stock has increased by 38.6% over the past three months, outperforming the industry growth of 13.9% [5] Regulatory Updates - VNDA has established a collaborative framework with the FDA to resolve disputes regarding tradipitant and Hetlioz, with an expedited re-review of the clinical hold on tradipitant's long-term studies now set for completion by December 5, 2025 [6][9] - The FDA has agreed to pause ongoing administrative proceedings related to VNDA's new drug application for tradipitant in gastroparesis until January 7, 2026 [10] - VNDA has submitted a Biologics License Application (BLA) for imsidolimab, a novel treatment for generalized pustular psoriasis, expanding its portfolio in rare diseases [13] Future Prospects - VNDA has multiple upcoming regulatory catalysts, including FDA reviews for Bysanti (milsaperidone) targeting bipolar I disorder and schizophrenia, with a target action date of February 21, 2026 [14]